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Evaluating the next generation of RSV
intervention strategies: a mathematical
modelling study and cost-effectiveness
analysis
David Hodgson1,2,3,4* , Richard Pebody5, Jasmina Panovska-Griffiths1,2,6†, Marc Baguelin4,7,8† and
Katherine E. Atkins7,9†
Abstract
Background: With a suite of promising new RSV prophylactics on the horizon, including long-acting monoclonal
antibodies and new vaccines, it is likely that one or more of these will replace the current monoclonal Palivizumab
programme. However, choosing the optimal intervention programme will require balancing the costs of the
programmes with the health benefits accrued.
Methods: To compare the next generation of RSV prophylactics, we integrated a novel transmission model with an
economic analysis. We estimated key epidemiological parameters by calibrating the model to 7 years of historical
epidemiological data using a Bayesian approach. We determined the cost-effective and affordable maximum purchase
price for a comprehensive suite of intervention programmes.
Findings: Our transmission model suggests that maternal protection of infants is seasonal, with 38–62% of infants
born with protection against RSV. Our economic analysis found that to cost-effectively and affordably replace the
current monoclonal antibody Palivizumab programme with long-acting monoclonal antibodies, the purchase price per
dose would have to be less than around £4350 but dropping to £200 for vaccinated heightened risk infants or £90 for
all infants. A seasonal maternal vaccine would have to be priced less than £85 to be cost-effective and affordable.
While vaccinating pre-school and school-age children is likely not cost-effective relative to elderly vaccination
programmes, vaccinating the elderly is not likely to be affordable. Conversely, vaccinating infants at 2 months
seasonally would be cost-effective and affordable if priced less than £80.
Conclusions: In a setting with seasonal RSV epidemiology, maternal protection conferred to newborns is also seasonal,
an assumption not previously incorporated in transmission models of RSV. For a country with seasonal RSV dynamics
like England, seasonal programmes rather than year-round intervention programmes are always optimal.
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Background
Respiratory syncytial virus (RSV) is the most common
cause of acute lower respiratory infection in children
under 5 years of age globally, causing 48,000–74,500
deaths annually [1]. The sole pharmaceutical prevention
strategy, a monoclonal antibody (Palivizumab), is costly
and only available to infants in high-income countries
and only to those at most risk of RSV-related complica-
tions [2]. This gap in prevention strategies leaves the
majority of infants vulnerable to infection.
There are currently over 40 RSV prophylactic candi-
dates in pre-clinical or clinical trials [3]; those furthest
along in development include long-acting monoclonal
antibodies (e.g. MEDI8897 by MedImmune) [4], and
maternal, childhood, and elderly vaccines (e.g. RSV F-
nanoparticle vaccine by Novavax, ChAd155-RSV by
GlaxoSmithKline, and Ad26.RSV.preF by Jensen, respect-
ively) [5, 6]. Although missing its primary endpoint, a
recent stage III trial of the Novavax RSV F-nanoparticle
vaccine showed promising results, preventing RSV-
related lower respiratory tract infections and hospitalisa-
tions in babies born to vaccinated mothers in the South
Africa site [5], while stage II trial results suggest that the
MedImmune MEDI8897 long-acting monoclonal anti-
bodies are effective at preventing RSV disease in neo-
nates for at least 150 days post-administration—five
times longer than a single dose of Palivizumab [4]. Stage
II trial results for the adenovirus vectored vaccines Glax-
oSmithKline ChAd155-RSV and Jensen Ad26.RSV.preF
suggest that they are well tolerated and safe in their re-
spective target groups of infants and the elderly, respect-
ively, though we currently lack efficacy results [6].
Deciding which, if any, of this suite of pharmaceutical
prophylactics to adopt requires an integrated approach in
which all the health benefits accrued by targeted specific
subpopulations (intervention strategies)—both by direct
and indirect protection and across all ages—can be accur-
ately compared. Moreover, with multiple new prophylac-
tics likely to arrive to license at a similar time,
understanding the relative efficiency of potential interven-
tion strategies at controlling RSV burden, and therefore
what we should be willing to pay for them, will dominate
decision-making on future RSV intervention strategies.
In this study, we developed such an integrated ap-
proach by combining a novel age-stratified epidemio-
logical transmission model for RSV into a cost-
effectiveness framework. The model was calibrated using
a Bayesian inference framework to 7 years of RSV inci-
dence data from England. The cost-effectiveness analysis
was undertaken according to the National Institute of
Clinical Excellence (NICE) reference case [7]. Using this
approach, we were able to determine the maximum pur-
chasing prices for the next generation of RSV interven-
tion strategies to be cost-effective and affordable.
Methods
RSV model structure
We modelled the number of individuals in six differ-
ent epidemiological states (M, S, E, I, A, and R).
When a susceptible individual (S) acquires infection,
they move to an exposed but not infectious state (E)
for an average of 1/σ days, after which they become
infectious with either symptomatic (I) or asymptom-
atic (A) infection. After an infectious period of 1/γ
days, individuals move to a protected state (R) for a
period of 1/ω days, after which they become suscep-
tible to reinfection (S). We assume that only babies
born to mothers who have recently been infected with
RSV and who therefore have high levels of antibody
(and thus, in state R) are maternally protected (M)
for a period of 1/ξ after birth, with the remaining ba-
bies born susceptible to infection (S) (Additional file 1:
Section 1) [8–11]. We tested this assumption to the
alternative where all babies are born with temporary
maternal immunity, similar to previous models (e.g.
Kinyanjui et al. [12]) using the deviance information
criterion (DIC) (Additional file 1: Section 1) [8–11].
We stratified individuals into 25 age groups (monthly
up to 11 months of age, and then 1, 2, 3, 4, 5–9, 10–
14, 15–24, 25–34, 35–44, 45–54, 55–64, 65–74, 75+
years) and also tracked the number of individuals
who had experienced zero, one, and two or more pre-
vious infections (denoted by the subscripts 0, 1, 2, 3).
Consistent with empirical data, we assume that the
proportion of individuals who experienced asymptom-
atic infection is dependent on age [13] and the dur-
ation of infection and susceptibility to infection are
dependent on the number of previous RSV infections
[14, 15]. We assume that the contact rate between
two age groups is proportional to the mean number
of daily physical and conversational contacts made
between those age groups—parameterised using em-
pirical data from England and Wales (Additional
file 1: Section 1) [8–11]. We captured the strongly
seasonal dynamics of RSV in temperate climates by
multiplying the per-contact transmission rate with a
seasonal forcing term (Additional file 1: Section 1)
[8–11].
To capture the current impact of administering Palivi-
zumab, we tracked infants who are eligible in England:
those born at less than 34 weeks gestational age are less
than 9 months of age at the start of the RSV season (Oc-
tober) and suffer from either bronchopulmonary dyspla-
sia or congential heart disease [2]. We refer to these
infants as very-high-risk (VHR). For VHR infants, we as-
sumed that 90% receive Palivizumab with 33.8% acquir-
ing immediate protection which lasts for an average of
1/ωpal = 150 days, after which they return to the primary
susceptible compartment (S0) [16].
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Model parameterisation and calibration
We used a Bayesian Markov chain Monte Carlo (MCMC)
approach [17] to fit the model to the confirmed number
of positive weekly RSV samples in England collected via
the Respiratory DataMart System (RDMS) between July
2010 and June 2017 [18]. We constructed the prior distri-
butions for all epidemiological parameters after a compre-
hensive synthesis of the literature (Table 1) (Additional
file 1: Section 2) [8, 13–15, 19–28]. We used a binomial
likelihood function that assumes an age-specific reporting
rate of RSV-positive samples. To estimate how the report-
ing rates of RSV infection varied across ages, we tested five
different assumptions about the age stratification (number
and age grouping) using the deviance information criter-
ion (DIC) (Additional file 1: Section 3) [17, 18, 25, 29, 30].
The output of the calibration is a joint posterior distribu-
tion for all the fitted parameters of the transmission
model. To compare our model to the weekly number of
RSV-positive samples, we multiplied the model-predicted
weekly incidence of symptomatic cases with the fitted age-
specific reporting rates.
Intervention model structure
Status quo
We assume that Palivizumab is currently administered
to 90% of VHR infants at birth between October to
February inclusive (PAL-VHR-S, Additional file 1:
Section 4) [28, 31–36]. We compare this status quo to
the following three alternative intervention strategies.
Long-acting monoclonal antibodies
We tracked the number of infants protected by long-
acting monoclonal antibodies, VM, who remain pro-
tected after birth for an average of 1/ωmab = 250 days
after which they return to S0 (Additional file 1: Section
4) [28, 31–36]. However, we relaxed this assumption in
an uncertainty analysis. We evaluated three seasonal
programmes that administer a single dose of long-acting
Table 1 Posterior distributions of the model parameters used in the transmission model of RSV. CrI credible interval
Parameter Mean value (95% CrI of posterior
where applicable)
Reference for fixed value
or prior distribution
μ Daily number of live births 1863 (fixed) [8]
1/ξ Average duration of maternally derived immunity (days) 133.5 (119.6–146.1) [19–21]
1/ω Average duration of post-infection immunity (days) 358.9 (350.7–364.7) [22, 23]
1/σ Average duration of exposure (days) 4.98 (4.54–5.37) [24]
1/γ0 Average duration of primary infection (days) 6.16 (5.68–6.63) [15]
g1 Decrease in secondary infection duration relative to primary 0.87 (0.83–0.91) [15]
g2 Decrease in subsequent infection duration relative to secondary 0.79 (0.73–0.86) [15, 24]
p<1 Proportion asymptomatic (< 1 years) 0.0916 (0.031–0.158) [13]
p1–4 Proportion asymptomatic (1–4 years) 0.163 (0.092–0.223) [13]
p5–14 Proportion asymptomatic (5–14 years) 0.516 (0.460–0.572) [13]
p15+ Proportion asymptomatic (15+ years) 0.753 (0.656–0.829) [13]
α Relative reduction in infectiousness for asymptomatic infections 0.634 (0.541–0.724) Fitted
qp Probability of RSV transmission per physical contact 0.0972 (0.093–0.099) Fitted
qc Relative reduction in probability of RSV transmission per
conversational contact compared to physical contact
0.998 (0.996–1.000) Fitted
b1 Relative amplitude of transmission during peak 1.998 (1.992–2.000) Fitted
φ Seasonal shift in transmission 0.614 (0.607–0.624) Fitted
ψ Seasonality wavelength constant 0.236 (0.220–0.252) Fitted
Susceptibility
δ1 Secondary infection (relative to primary) 0.89 (0.85–0.93) [14]
δ2 Tertiary infection (relative to secondary) 0.81 (0.74–0.85) [14]
δ3 Subsequent infections (relative to tertiary) 0.33 (0.31–0.37) [14]
Probability that an RSV infection is reported
ϵj 0–4 years exp(− 4.602–0.233j) [14, 25]
ϵ17 5–54 years 0.0000305 (0.0000290–0.0000320) [22]
ϵ18 55+ years 0.000147 (0.000134–0.000160) [22]
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monoclonal antibodies at birth (i) to those who are
currently eligible for Palivizumab (MAB-VHR-S), (ii) to
both VHR infants and infants who are at heightened risk
(HR) of developing complications due to respiratory
disease (MAB-HR-S), and (iii) to all infants regardless of
risk (MAB-ALL-S). We evaluated two additional sea-
sonal programmes that extend administration (iv) to all
VHR and high-risk (HR) infants under 6 months (MAB-
HR-S+) and (v) to all infants under 6 months (MAB-
ALL-S+) throughout October only [6]. We assume that
these programmes would replace the existing Palivizu-
mab programme, that they all achieve the same coverage
as Palivizumab, and that the efficacy per course is 70.1%
(95% confidence Interval (CI) 52.3–81.0%) [4, 37].
Childhood/elderly vaccination
We assumed that a single dose of a vaccine conferred
the same protection as that of a natural infection, such
that 83.0% (95% CI 75.0–88.0%) of vaccinated individ-
uals in the ith previous infection group who are suscep-
tible (Si) are moved to the respective recovered group
(Ri) after a delay reflects the build-up of antibody im-
munity (Additional file 1: Section 4) [28, 31–36, 38]. We
considered two vaccination programmes aimed at in-
fants aged 2 months old: one administered seasonally
(VAC-INF-S) and one year-round (VAC-INF-A), both
achieving a coverage of 90%, consistent with the DTaP/
IPV/Hib/HepB/PCV/Rota primary series vaccination
coverage in England. We also considered two seasonal
vaccination programmes aimed at elderly persons: one
for those aged 75 years and older (VAC-75-S) and one
for those aged 65 years and older (VAC-65-S), both
achieving a coverage of 70%, consistent with vaccination
coverage for the elderly influenza vaccine programme
[39, 40]. Finally, we considered three seasonal pro-
grammes aimed at pre-school children (aged 2–4 years,
VAC-2-4-S) and school-age children (aged 5–9 years,
VAC-5-9-S, and aged 5–14 years, VAC-5-14-S) that
achieve a coverage of 45% and 60%, respectively, consist-
ent with the live attenuated influenza vaccination
programme in England [39]. We assumed that the speed
at which this coverage is achieved is age-dependent and
consistent with that achieved for influenza vaccination.
For all the childhood/elderly vaccination programmes
considered, we assumed that they would be administered
in addition to the existing Palivizumab programme in
the UK.
Maternal vaccination
To evaluate the direct effect on infants of vaccinating
pregnant women, we used the results of Novavax’s mater-
nal vaccine stage III trial that found 41.4% (95% CI 4.1–
64.2) of infants born to these mothers are protected
against infection for the first 3 months of life (Table 2) [5].
Consistent with the trial, we assume pregnant women are
vaccinated at any point between 28 and 32weeks gestation
(Additional file 1: Section 4) [28, 31–36].
To evaluate the indirect effects of maternal vaccination
while maintaining computational tractability and epi-
demiological realism, we used a previously published
method for evaluating the impact of parental vaccination
[36]. In brief, this method tracks the number of mothers
of infants less than 1 year of age, and the number of
these women who are participating in a maternal vaccin-
ation programme. The contact rate between mothers
and their children is explicitly modelled using the num-
ber of household and non-household contacts, as re-
ported by the Great Britain arm of the POLYMOD
study [10, 11]. Accordingly, the force of infection be-
tween mothers and their infants is updated to reflect the
vaccination status of the mother. We assume that the
vaccinated mothers are themselves temporarily protected
from infection consistent with the protection afforded by
the childhood/elderly vaccination assumptions above
(Additional file 1: Section 4) [28, 31–36]. We considered
two maternal vaccination programmes, which are given in
combination with the existing Palivizumab programme: a
seasonal programme (MAT-S) and one administered
year-round (MAT-A), with a coverage of 60% as observed
for prepartum Tdap vaccination in England [5, 39].
Optimising seasonal administration
To allow an unbiased comparison of the seasonal pro-
grammes, our framework assumes the programmes are
given continuously for 5 months. For programmes that
administer Palivizumab and long-acting monoclonal
antibodies, we assume administration occurs during the
Palivizumab-recommended time period of October to
February. To determine the period of administration for
the remaining intervention programmes, we chose the 5-
month period that resulted in the largest QALY gain
relative to status quo.
Economic model
Clinical outcomes
For each intervention strategy, the economic model esti-
mated the number of cases averted for five different
RSV-associated clinical outcomes: symptomatic infec-
tion, GP consultations, hospital admissions, hospital bed
days, and deaths. The number of symptomatic cases
averted is estimated directly from the transmission
model. To estimate the number of cases averted for the
remaining four outcomes, we first calculated the per-
infection probability that an individual experiences each
clinical outcome by dividing the reported annual inci-
dence rates for each outcome taken from previous
burden studies in England (Additional file 1: Section 5)
[41–51] by the transmission model-estimated annual
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incidence for RSV under the status quo. Then, to calcu-
late the number of cases averted for each outcome under
each intervention strategy, we multiplied the estimated
number of RSV cases averted from the intervention
model by the per-infection probability of each outcome.
Quality of life loss
In line with our previously estimated quality-adjusted life
year (QALY) loss estimates per RSV episode for Eng-
land, we assume that each GP consultation or hospital-
isation resulted in a QALY loss of 4.098 × 10−3 (0.624 ×
10−3–13.141 × 10−3) and 2.990 × 10−3 (0.346 × 10−3–
11.387 × 10−3) for under fives and over fives, respectively,
while other symptomatic non-healthcare seeking infec-
tions resulted in a QALY loss of 2.336 × 10−3 (95% CI
0.269 × 10−3–9.255 × 10−3) and 1.448 × 10−3 (95% CI
0.135 × 10−3–5.928 × 10−3) [52]. QALY loss due to death
was commensurate with the remaining number of ex-
pected healthy years of life remaining in the individual
(Additional file 1: Section 5) [41–51].
Costs
Costs were calculated in 2018 GBP, from the perspective
of the NHS. The cost per GP consultation was calculated
by assuming an average GP consultation time of 9 min
at a cost of £4.00 a minute (£36.00) [53, 54]. The cost
per hospital bed day for children less than 5 years of age
was calculated using the non-elective costs for paediatric
bronchitis (Health Resource group (HRG) PD15A–D)—
the main cause of RSV-associated hospitalisations [55,
56]. The cost per hospital bed day for children 5 years
and older was determined using the non-elective costs
for unspecified acute lower respiratory infection (HRG
DZ22K–Q) [56]. We assumed maternal, infant, and eld-
erly vaccines take 15 min to administer in a GP clinic at
a cost of £9 per course (assuming one dose per course)
[54]. Similarly, we assumed long-acting monoclonal anti-
bodies and Palivizumab take 15 min to administer in
hospital by a nurse at a cost of £11.50 per course for
long-acting monoclonal antibodies and £57.50 per course
(5 doses) for Palivizumab [54]. A course of Palivizumab
costs £4035 (5 doses at £807 each) (see Table 3) [56].
Cost-effectiveness analysis
We conducted three separate cost-effectiveness analyses.
First, we calculated the incremental cost-effectiveness ra-
tio (ICER) of replacing the Palivizumab with any of the
long-acting monoclonal programmes (MAB-VHR-S,
MAB-HR-S, MAB-HR-S+, MAB-ALL-S, and MAB-ALL-
S+). Second, we calculated the ICERs of supplementing
Table 2 Intervention model parameters. CrI credible interval
Parameter Mean value (95% CI where applicable) Reference
Palivizumab
Delay between administration and protection (days) Immediate (fixed) [16]
ωpal Average period of protection (days) 150 (fixed) [16]
epal Efficacy on VHR infants (%) 33.8 (0.0–66.6)
1 [16]
Long-acting monoclonal antibodies
Delay between administration and protection (days) Immediate (fixed) [4]
ωmab Average period of protection (days) 275 (fixed) [4]
eSmab Efficacy against symptomatic infection (%) 70.1 (52.3–81.0)
2 [37]
eHmab Efficacy against hospitalisation (%) 78.4 (51.9–90.3)
3 [37]
Childhood/elderly vaccine
dvac Delay between administration and protection (days) 11.4 (2.8–22.1)
4 [38]
ω Average period of protection (days) Same as post-infection immunity (1/ω) [38]
evac Efficacy against all infections (%) 83.0 (75.0–88.0)
5 [38]
Novavax vaccine
d2mat Average period of protection (days) 133.5 (119.6–146.1) Same as maternally derived immunity
eSmat Efficacy against symptomatic infection (%) 41.4 (4.1–64.2)
6 [5]
eHmat Efficacy against hospitalisations (%) 53.5 (23.0–71.9)
7 [5]
Fitted distributions
1Gamma (3.7623, 0.0898)
2W(11.898, 0.732)
3W(11.611, 0.819)
4W(2.42, 12.87)
5W(31.464, 0.845)
6W(3.327, 0.461)
7W(5.354, 0.580)
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the Palvizumab programme with the childhood or eld-
erly vaccine programmes (VAC-INF-S, VAC-INF-A,
VAC-2-4-S, VAC-5-9-S, VAC-5-14-S, VAC-75-S, VAC-
65-S). Third, we calculated the ICER of supplementing
the Palivizumab programme with the maternal vaccine
programmes (MAT-S, MAT-A). For each of these three
cost-effective analyses, using the non-dominated pro-
grammes only, we calculated the maximum price per
course that would make each strategy cost-effective, as-
suming a cost-effectiveness threshold of £20,000/QALY
(Additional file 1: Section 5) [41–51]. All costs and ef-
fects were discounted at a rate of 3.5% over a 10-year
time horizon [7]. For each intervention strategy, we cal-
culated the credibility intervals using 1000 Monte Carlo
samples. For each Monte Carlo sample, we first esti-
mated the number of RSV cases averted over the time
horizon per outcome for an intervention strategy by
sampling from the joint posterior distribution and run-
ning the intervention model for 10 years. Then, by sam-
pling from the per-infection probability of each outcome
occurring, we converted the number of RSV cases
averted to the number of outcomes averted. Finally, we
combined sampled values from the cost distributions
with the number of each clinical outcome averted to
Table 3 Health and economic parameters used in the cost-
effectiveness analysis
Parameter Mean value (95% CI
where applicable)
Reference
T Time horizon 10 years –
r Discount rate 3.5% [7]
Probability of clinical outcomes
rG
a Per-infection probability
of GP consultation
0–4 years:
0.006–0.065
[41]
5–14 years:
0.017–0.018
[44]
15+ years: 0.014–
0.132
[42]
rD
a Per-infection probability
of death
0–4 years: 8.197 ×
10−6–3.698 × 10−5
[41]
5–14 years: 6.731 ×
10−6–6.896 × 10−6
[44]
15+ years: 4.663 ×
10−6–0.002
[42]
rH
a,r Per-infection probability
of hospital admissions
VHR, 0–8 months:
0.133–0.391
[57]
HR, 0–11 months:
0.013–0.130
[46]
NR, 0–11 months:
0.010–0.097
[46]
NR, 1–4 years:
0.004–0.008
[29]
NR, 5–64 years: 4.688
× 10−5–8.004 × 10−5
[44]
NR, 65+ years: 6.197
× 10−5–0.019
[42]
rB
a,r Number of hospital bed
days per hospitalisation
VHR, 0–8 months: 8–
25
[57]
HR, 0–11 months: 5–7 [46]
NR, 0–11 months: 1–5 [46]
NR, 1–64 years: 2 [47]
NR, 65+ years: 3 [48]
Costs
Per GP visit
ΘGP All ages £36.00 (fixed) [53, 54]
Per hospital bed day
ΘaH Paediatric (< 5 years of
age)
£725.29 (718.13–
733.99)1
[56]
ΘaH Adult (≥ 5 years of age) £425.24 (415.16–
435.70)2
[56]
Administration of prophylactics (per course)
Δpal Palivizumab £57.50 (fixed) [54]
Δmab La-mABs £11.00 (fixed) [54]
Δmat Maternal vaccine £9.00 (fixed) [54]
Δvac Vaccine £9.00 (fixed) [54]
Table 3 Health and economic parameters used in the cost-
effectiveness analysis (Continued)
Parameter Mean value (95% CI
where applicable)
Reference
Purchasing prices (per course)
ρpal Palivizumab £4035.50 (fixed) [56]
ρX La-mABs, Maternal
vaccine and vaccine
Not known
QALY loss
Symptomatic infection
QaS Paediatric (< 5 years of
age)
2.336 × 10−3 (0.269 ×
10−3–9.255 × 10−3)3
[52]
QaS Adult (≥5 years of age) 1.448 × 10
−3 (0.135 ×
10−3–5.928 × 10−3)4
[52]
Hospital admissions
QaH Paediatric (< 5 years of
age)
4.098 × 10−3 (0.624 ×
10−3–13.141 × 10−3)5
[52]
QaH Adult (≥5 years of age) 2.990 × 10
−3 (0.346 ×
10−3–11.387 × 10−3)6
[52]
Deaths
Life expectancy 81.0 years [51]
QaS Age-specific QALY loss See Additional file 1:
Section 5.2.
Fitted distributions
1N(725.293, 4.1264
2N(425.242, 5.2781
3Gamma(1.57764, 0.0014807)
4Gamma(1.41075, 0.0010264)
5Gamma(2.0017, 0.00204726)
6Gamma(1.60289, 0.00186539)
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calculate the distribution of the maximum price per
prophylactic course.
Affordability
Consistent with NICE guidelines, an intervention strat-
egy is considered affordable in England if it costs less
than £20 million annually during the first 3 years of im-
plementation [58]. Using this definition, we calculated
the affordable purchasing price per course for each non-
dominated programme, by subtracting the total, undis-
counted cost of administering the intervention strategy
for the first 3 years from £60 million (3 years at £20 mil-
lion each) and dividing by the total number of courses
given during this period [58].
Calculations and code
The model was programmed in C++ with the code avail-
able at https://github.com/dchodge/rsv_trans_model. The
figures were generated in Mathematica version 11.0.0 [59].
Role of the funding source
The funding source had no role in this study.
Results
RSV epidemiology
Our model comparison analyses suggested that maternal
immunity was conferred seasonality according to the
prevalence of recently infected pregnant mothers (Add-
itional file 2: Fig. 1). Furthermore, we found that there is
a likely exponential decrease in the reporting rates be-
tween the ages of 0–4 years, and fixed reporting rates for
5–54 years and 55 years and over (Additional file 2:
Fig. 2).
The model reproduces the age distribution of RSV in-
cidence (Fig. 1a–c, Additional file 2: Fig. 3–4). Using the
calibration method, we are able to estimate parameters
that have been difficult to evaluate directly from epi-
demiological studies (Additional file 2: Fig. 5). First, our
model predicts that between 68 and 81% of infants ex-
perience an RSV infection in their first year of life, with
subsequent infection risk generally decreasing with age
(Fig. 1d). Deviations away from this decreasing trend
occur in age groups which have the highest number of
daily contacts (Fig. 1d). Second, we estimated the aver-
age duration of maternal immunity and post-infection
immunity as 134 days (95% CrI 120–146) and 359 days
(95% CrI 351–365), respectively. While our estimate for
the duration of maternal immunity agrees with previous
observations [60], our estimate for the post-infection im-
munity is slightly longer than previous studies [23, 60].
This difference may be due to study type or setting. For
instance, an experimental challenge study found reinfec-
tion was likely after 2–6 months [23], and a birth cohort
study in Kenya found most reinfections occur 6–12
months after primary infection [60]. Third, the model
estimated that asymptomatic infections are 63% (95%
CrI 54–72%) as infectious as symptomatic infections
(Table 1). This value is commensurate with the relative
decrease in the viral load in asymptomatic infections
when compared to symptomatic [13]. Finally, we found
that 62% of babies are born with protection to RSV dur-
ing March, compared with 38% prior to the RSV season
in September and October (Additional file 2: Fig. 2).
Probability of clinical outcomes
The average probability of consulting a GP due to RSV
infection is highest in children less than 5 years of age
(0.006–0.065) and adults 65 years and older (0.103–
0.132). The average probability of death per-infection is
highest in adults over 75 years (0.002) and rare in chil-
dren and other adults in the remaining age groups (less
than 3 in every 100,000 infections). The average prob-
ability of hospitalisation is highest in infants below 1 year
of age (0.010–0.097), with peak risk occurring at 1
month of age, and lowest risk in persons aged 5–45 years
of age (less than one in every 10,000 infections). HR and
VHR infants have an increased risk of hospitalisation of
0.0138–0.129 and 0.14–0.37, respectively, compared with
other infants (0.010–0.097). Similarly, the average num-
ber of bed days experienced per hospitalisation is great-
est in infants less than 1 year of age (1–5) with the
longest stays occurring at 1 month of age, and HR and
VHR infants seeing an increase in the number of bed
days of 5–7 and 8–25, respectively (Additional file 2:
Fig. 6).
Impact of intervention strategies
Long-acting monoclonal antibodies
The seasonal programmes aimed at VHR infants or
VHR and HR infants (MAB-VHR-S and MAB-HR-S, re-
spectively) are the most efficient at preventing RSV hos-
pitalisations, preventing 51 (95% CI 43–55) and 36 (95%
CI 30–39) hospital cases per 1000 administered courses
(Fig. 2a). These intervention programmes are not effect-
ive in raising the median age of primary infection
(Fig. 2b).
Childhood/elderly vaccination
We found that to maximise the health benefit of the sea-
sonal vaccination programmes, the optimal period of ad-
ministration is between November and March for
elderly programmes, October to February for the VAC-
2-4-S and VAC-5-9-S programmes, and August to De-
cember for the VAC-5-14-S programme (Additional file
2: Fig. 7). Vaccinating individuals 65 years and over is
the most effective programme at preventing the total
number of GP consultations, hospitals, bed days, and
deaths (23%, 25%, 26%, and 49% reductions, respectively)
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(Fig. 2a). However, the large size of the target group
means this programme is inefficient, preventing 19.03,
1.63, 4.34, and 0.25 cases of GP consultations, hospitals,
bed days, and deaths respectively per 1000 vaccine
courses. The most effective school-age programme is the
5–14-year-old programme, preventing 4.5% (95% CrI
3.9–5.4) of hospitalised cases. School-age programmes
confer considerable herd protection, with 91.5% of the
5–9-year-old programme and 94.9% of 5–14-year-old
programme of averted hospitalised cases due to indirect
protection (Fig. 2c, Additional file 2: Fig. 8).
Maternal vaccination
Our results suggest that, to maximise the health benefit
for a seasonal third trimester maternal programme, the
optimal period of administration is from August until
December (Additional file 2: Fig. 7). Such a programme
prevents 8.5 (95% CrI 7.4–10.3) hospitalised cases per
1000 vaccine courses administered, with 22–30% of the
hospitalised cases prevented in infants less than 1 year of
age attributable to indirect protection from vaccinated
mothers (Fig. 2d). Though the seasonal maternal
programme is more efficient than its year-round
Fig. 1 The calibrated model and the incidence of RSV-associated outcomes. a The model-estimated mean number of new weekly infections fit to
the reported RSV-positive samples from July 2010 to July 2017 in England. b, c Model-predicted mean annual number of new infections per age
group with the reported RSV-positive samples. d The model-predicted incidence of any and symptomatic RSV infections. e Age group attribution
to each healthcare outcome
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counterpart, it is less efficient at preventing hospitalised
cases than any of the long-acting monoclonal antibody
programmes.
Maximum purchasing price
Long-acting monoclonal antibodies
The maximum purchasing price per course for the long-
acting monoclonal antibody programme to be cost-
effective when administered seasonally to only the VHR
infants is £4342.97 (95% CrI £4126.31–4462.25) (Fig. 3a).
For this seasonal programme to remain cost-effective
after extending to HR neonates (MAB-HR-S), and then
to all HR infants less than 6 months at the start of
season (MAB-HR-S+), requires substantially lower
maximum purchasing prices per course of £201.15 (95%
CrI £149.61–243.42) and £87.03 (95% CrI £64.80–116.99),
respectively (Fig. 3a). If the duration of protection varies
between 150 and 365 days, the maximum purchasing price
for the MAT-HR-S programme would also vary between
£185.79 and 215.02, respectively (Fig. 3b).
Maternal vaccination
The year-round maternal vaccination programme
(MAT-A) was dominated by the seasonal strategy
(MAT-S). The maximum purchasing price per course
for the seasonal maternal vaccination (MAT-S) to be
cost-effective is £85.27 (95% CrI £77.79–93.80)
(Fig. 3a).
Fig. 2 The impact of the 14 intervention programmes. a Total effectiveness (direct and indirect effects) of each intervention programme at preventing five
healthcare outcomes (symptomatic infection, hospital admission, death, GP consultations, and bed days). b Efficiency of programmes. c, d Effectiveness of each
intervention strategies in terms of direct (grey) and indirect effects for symptomatic infection (c) and hospitalised cases (d). eMedian age of primary infection
for long-acting monoclonal antibodies and maternal vaccines
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Childhood/elderly vaccination
The year-round vaccine programme aimed at infants 2
months of age (VAC-INF-A) is dominated by its sea-
sonal counterpart (VAC-INF-S), while the 65 years and
over programme (VAC-65-S) is dominated by the 75
years and older programme (VAC-75-S). Further, the
pre-school (VAC-2–4-S) and school-age programmes
(VAC-5–9-S, VAC-5–14-S) are subject to extended
dominance by the 75 years and older programme (VAC-
75-S). For the seasonal vaccine programme aimed at in-
fants aged 2months of age (VAC-INF-S), the maximum
purchasing price per course to remain cost-effective is
£94.76 (95% CrI 89.09–99.24). Targeting those aged 75
years (VAC-75-S) and older requires a lower purchasing
price per course of £20.71 (95% CrI 10.32–34.64)
(Fig. 3a).
Affordability
The long-acting monoclonal antibody programmes
MAB-VHR-S, MAB-HR-S, and MAB-HR-S+ and the
seasonal maternal programme (MAT-S) are affordable if
implemented for a cost-effective purchasing price per
course (affordable thresholds are £9395.75, £1712.46,
£873.08, and £121.02, respectively). The seasonal infant
programme aimed at 2-month-olds (VAC-INF-S) and
the 75 years and older programme (VAC-75-S) are
affordable if implemented for £79.62 and £3.63, respect-
ively—81% and 16% of the estimated mean maximum
purchasing price per course (Table 2).
Discussion
This study used a mathematical modelling approach cal-
ibrated to 7 years of RSV incidence data to evaluate RSV
epidemiology and surveillance in a developed country.
Integrating this model into a cost-effectiveness frame-
work, we evaluated the likely maximum dose prices of
the new generation of RSV preventive pharmaceuticals
to make them cost-effective and affordable in England.
Our epidemiologic analysis found that maternal protec-
tion for infants is likely seasonal, with more babies born
with protection against RSV towards the end of the RSV
season in March. Our economic analysis found that re-
placing the existing seasonally administered Palivizumab
programme with long-acting monoclonal antibodies
Fig. 3 Maximum purchase price for a course of treatment to remain cost-effective assuming a cost-effectiveness threshold of £20,000 QALY. a Probability of
cost-effectiveness for each of the non-dominated programmes over a range of purchasing prices. b Sensitivity analysis on the duration of protection for the
monoclonal antibodies and its effect on the maximum purchasing price per course
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(MAB-VHR-S) would be cost-effective and affordable at
a maximum course price of £4403 (95% CrI 4338–4511).
Extending the programme to heightened risk (MAB-HR-S)
or all infants (MAB-ALL-S) would remain cost-effective
and affordable at approximately £200 and £90, respectively.
A seasonal maternal vaccination programme (MAT-S)
would be cost-effective and affordable with a maximum
purchasing price per course of £85 (95% CrI 79–91).
This is the first study to use a dynamic transmission
model to evaluate how Palivizumab, monoclonal anti-
bodies, and maternal vaccines impact the incidence of
RSV-related healthcare outcomes within a single frame-
work. Consequently, this model gives a comprehensive
overview of the impact of all currently proposed RSV
programmes. This study is also the first to directly link
the impact of potential programmes from a dynamic
transmission model to a cost-effectiveness analysis
(CEA) according to the NICE reference case—the gold
standard approach for CEA in England and Wales, and
the first to use EQ-5D-based QALY estimates for RSV.
The CEA accounts for both the direct and indirect
effects of intervention strategies. This approach is of par-
ticular importance when comparing the health benefits
of vaccinating school-age children through which all re-
ductions in hospitalisations are through indirect protec-
tion of other high-risk groups, with those of providing
direct protection to newborns where all averted cases
are in the newborns themselves.
Our model is the first to test the hypothesis that ma-
ternal protection to newborns is seasonal, contrary to
the routine assumption in models in which all babies are
born with protection to RSV. We found evidence for our
alternative hypothesis. This seasonal change in the num-
ber of protected newborns could provide an explanation
for previous findings that hospitalisation rates increase
for babies born at the start of the RSV season, when our
model predicts the lowest fraction of maternally pro-
tected infants, and infants born at the end of the RSV
season when the maternal protection is highest experi-
ence the lowest risk of RSV-related hospitalisation [61].
Epidemiological evidence for seasonal changes in mater-
nal protection has also been provided in studies looking
at seasonal changes in RSV-specific antibody level from
cord titres at birth [26]. As cord titre influences the rate
of severe infections in the first year of life [21], seasonal
changes could indicate temporal vulnerability in the
infant population.
The maternal vaccine in this model is based on Nova-
vax’s RSV F-nanoparticle formulation. Recent stage III
trial results for this product failed to meet its primary
endpoint of 40% efficacy against RSV lower respiratory
tract infections (LRTI) during the first 3 months of life
across all trial sites. However, variations in efficacy were
observed depending on region and gestation age at
administration. Regional variation in efficacy saw South
Africa with promising efficacy estimates of 57% (95% CI
33–73%) against RSV LRTI, whereas the US site saw no
evidence of efficacy [5]. Although in this analysis, we as-
sume the efficacy of the maternal vaccine is as estimated
across all sites, we acknowledge that care should be
taken when these results are projected onto the UK,
which experiences seasonal RSV similar to the US trial
site. Efficacy was also found to vary with gestational age
at administration, with vaccination at the start of the
third trimester (28–32 weeks) experiencing an efficacy of
54% (95% CI 23–72%) against RSV-associated hospital-
isation and showing superior antibody transfer when
compared to administration later in the third trimester
(efficacy of 26% (95% CI − 23–56)). In our study, we
have chosen the efficacy given at 28–32 weeks gestation
as the healthcare delivery system in England is such that
specific uptake periods are feasible in GP clinics if
individuals are notified at the relevant time. However,
uptake during this specific window may be less feasible
in countries with differing healthcare policy, and thus,
lower coverage rates may be observed than used in this
study.
There are two potential intervention programmes
against RSV which we did not evaluate in this study but
may be suitable for further consideration. First, we did
not examine targeted vaccination of high-risk elderly
due to lack of data on clinical risk-specific hospitalisa-
tion and mortality rate within this age group. Second,
we did not consider combined approaches, primarily be-
cause it is not possible to determine unique maximum
purchasing prices per dose for multiple prophylactics
simultaneously. However, for some approaches that
combine strategies which prevent disease in different age
groups (e.g. elderly and infant vaccination), the max-
imum purchase price for the combined approach will be
approximately the sum of that for both strategies. Deter-
mining the cost-effectiveness of combination approaches
which prevent disease in similar age groups (e.g. mater-
nal and long-acting monoclonal antibody programmes)
will be possible when the purchasing price for at least
one of the strategies has become available.
Though the results of this analysis suggest that the
long-acting monoclonal antibodies and maternal pro-
grammes are cost-effective, implementation of these
programmes will present clinical and logistical chal-
lenges that this analysis has not considered. For example,
we assume the same administration price per dose for
all the monoclonal antibody programmes. However, ad-
ministration of monoclonal antibodies to the under 6
months, rather than just newborns, will likely be more
expensive and achieve lower rates of uptakes, all else
equal, as they will need to make a separate appointment
at a GP or hospital setting for dose administration.
Hodgson et al. BMC Medicine          (2020) 18:348 Page 11 of 14
Consequently, our results may overestimate the impact
and cost-effectiveness of these programmes. Further, in
estimating the per-infection risk for RSV-related out-
comes, there were no clinical-risk-specific estimates for
death and for GP consultations available in the litera-
ture, meaning the probability of these outcomes occur-
ring may be underestimated in VHR or HR infants,
implying costs and QALY burden of some of the inter-
vention strategies may be conservative. Further studies
which help estimate the burden of specific outcomes in
England would help reduce uncertainty and increase the
accuracy of the model predictions.
Conclusions
In this study, we have used a Bayesian approach to syn-
thesise existing epidemiological and clinical information
to estimate the uncertainty in the model parameters and
to incorporate uncertainty arising from these parameter
estimates to help inform decision-makers about the
implementation of new RSV intervention strategies. Our
analysis finds that, regardless of the intervention strat-
egy, seasonal administration of a programme is always
optimal. Moreover, we found little evidence that strat-
egies aimed at children 2 years and older and those tar-
geted at the elderly would be cost-effective or affordable,
respectively. In contrast, long-acting monoclonal anti-
bodies and maternal vaccines may be a cost-effective
replacement or addition to the existing Palivizumab
programme, respectively. The scope of the intervention
programme however will depend on the purchasing
price at when these pharmaceuticals are made available.
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